[{"data":1,"prerenderedAt":65},["ShallowReactive",2],{"q-nurse-114-2-basic-medicine-026":3},{"subject":4,"subjectSlug":5,"subjectFullName":6,"question":7,"related":34,"lastmod":64},"基礎醫學","basic-medicine","基礎醫學(包括解剖學、生理學、病理學、藥理學、微生物學與免疫學)",{"id":8,"webId":9,"year":10,"session":11,"subject":4,"number":12,"stem":13,"options":14,"answer":19,"answerNote":20,"images":21,"explanation":22,"explanationDeep":23,"topics":24,"freq":11},"nurse-114-2-基礎醫學-026","nurse-114-2-basic-medicine-026",114,2,26,"3 歲男性，右側睪丸有一個腫瘤，抽血發現血清中的甲型胎兒蛋白（α -fetoprotein）異常升高，他的睪丸腫瘤最可能是那一種？",{"A":15,"B":16,"C":17,"D":18},"卵黃囊瘤（yolk sac tumor）","絨毛膜癌（choriocarcinoma）","淋巴癌（lymphoma）","胚胎性癌（embryonal carcinoma）","A",null,[],"本題考點在於生殖細胞腫瘤的腫瘤標記對應。依腫瘤標記診斷,甲型胎兒蛋白(α-fetoprotein, AFP)顯著升高的睪丸生殖細胞瘤是卵黃囊瘤(yolk sac tumor),又稱內胚竇瘤,為幼兒最常見的睪丸生殖細胞腫瘤,故選 A。B 絨毛膜癌分泌的是 β-hCG 而非 AFP;C 淋巴癌不分泌 AFP,且好發於年長者;D 胚胎性癌雖屬生殖細胞瘤,但典型 AFP 升高並不如卵黃囊瘤專一,且多見於成人。故正解為 A。","標記對照:AFP↑→卵黃囊瘤;β-hCG↑→絨毛膜癌;兩者皆可能升高→混合型生殖細胞瘤;純精原細胞瘤(seminoma)AFP 正常。組織學上卵黃囊瘤可見 Schiller-Duval 小體。幼兒睪丸腫瘤以卵黃囊瘤最常見,是重要考點。",[25,27,30,32],{"term":26,"count":11},"卵黃囊瘤",{"term":28,"count":29},"甲型胎兒蛋白 AFP",1,{"term":31,"count":29},"Schiller-Duval 小體",{"term":33,"count":29},"生殖細胞腫瘤標記",[35,39,44,49,54,59],{"webId":36,"stem":37,"number":38,"year":10,"session":11},"nurse-114-2-basic-medicine-027","關於 IgA 腎病變（IgA nephropathy）的敘述，下列何者最不適當？",27,{"webId":40,"stem":41,"number":42,"year":43,"session":29},"nurse-115-1-basic-medicine-023","下列何者不屬於體染色體（autosome）數量異常的疾病？",23,115,{"webId":45,"stem":46,"number":47,"year":48,"session":29},"nurse-106-1-basic-medicine-017","在肌肉收縮與舒張過程（muscle contraction\u002Frelaxation cycle）中，ATP 結合於下列那一分子？",17,106,{"webId":50,"stem":51,"number":52,"year":53,"session":29},"nurse-107-1-basic-medicine-055","有關第一代 H 1 組織胺（histamine）受體拮抗劑（如 Chlorpheniramine 與 Diphenhydramine），其主要副作用之敘述，下列何者錯誤？",55,107,{"webId":55,"stem":56,"number":57,"year":58,"session":11},"nurse-108-2-basic-medicine-019","若血壓維持不變，血管半徑變為原來的兩倍，此時流經此條血管的血流量將變為：",19,108,{"webId":60,"stem":61,"number":62,"year":63,"session":11},"nurse-109-2-basic-medicine-053","下列何種給藥途徑的生體可用率（bioavailability）最佳？",53,109,"2026-09-04",1788510758736]